Core Viewpoint - Nuvectis Pharma, Inc. is hosting a virtual Key Opinion Leader Meeting on December 2, 2025, to discuss the NXP900 Phase 1b Program in Advanced Solid Tumors, particularly its combination with osimertinib in non-small cell lung cancer [1][2]. Company Overview - Nuvectis Pharma, Inc. is a clinical stage biopharmaceutical company focused on developing innovative precision medicines for serious unmet medical needs in oncology [1][8]. - The lead drug candidate, NXP900, is an oral small molecule inhibitor targeting the SRC Family of Kinases (SFK), including SRC and YES1, designed to inhibit both catalytic and scaffolding functions of the SRC pathway [6][8]. NXP900 Development - NXP900 has completed a Phase 1a dose escalation study in patients with advanced solid tumors and is currently undergoing a Phase 1b single agent dose expansion study [7][8]. - A drug-drug interaction study has been completed, supporting the initiation of enrollment in the Phase 1b dose expansion combination arm, expected to begin by the end of 2025 [7]. Key Opinion Leaders - The meeting will feature Dr. Alexander Spira, Chief Scientific Officer of NEXT Oncology, and Dr. Asier Uncita-Broceta, Professor of Chemistry at the University of Edinburgh, who will discuss NXP900's development program and clinical data [2][4][5].

First-of-its-Kind Investment Provides Direct Exposure to Telegram's $3 Billion Projected Annual Revenue paying ~9% APY with Convertible discount of 20% in a Telegram Change of Control Scenario, in addition, ATON will use the 9% APY to accumulate more TON Coin for its Digital Asset TreasuryTORTOLA, BVI, Nov. 25, 2025 (GLOBE NEWSWIRE) -- AlphaTON Capital Corp. (NASDAQ: ATON), a leading digital asset technology company focused on the Telegram and TON ecosystem, today announced its strategic interest in acquiri ...

Core Viewpoint - Compass Therapeutics, Inc. is actively engaging with investors through participation in key healthcare conferences in December 2025, highlighting its focus on oncology and proprietary antibody-based therapeutics [1][2]. Group 1: Upcoming Investor Events - Compass Therapeutics will participate in the Piper Sandler 37th Annual Healthcare Conference on December 2, 2025, at 8:00 AM ET in New York, NY [2]. - The company will also attend the 8th Annual Evercore Healthcare Conference on December 4, 2025, at 10:00 AM ET in Coral Gables, FL [2]. - Presentations from these events will be archived for 90 days on Compass' Events page, allowing for virtual/replay availability [2]. Group 2: Company Overview - Compass Therapeutics is a clinical-stage biopharmaceutical company focused on developing proprietary antibody-based therapeutics for oncology [4]. - The company’s research emphasizes the interplay between angiogenesis, the immune system, and tumor growth, aiming to create a robust pipeline of novel product candidates [4]. - The therapeutic strategies include targeting angiogenesis, inducing immune responses, and overcoming immunosuppressive mechanisms utilized by tumors [4]. - Founded in 2014, Compass Therapeutics is headquartered in Boston, Massachusetts [4].

Core Insights - Black Rock Coffee Bar, Inc. will participate in the Morgan Stanley Global Consumer & Retail Conference on December 2, 2025, in New York, NY, including 1x1 meetings and a fireside chat at 3:00 p.m. EST [1] - A live webcast of the fireside chat will be available on the investor relations section of Black Rock Coffee Bar's website [2] Company Overview - Black Rock Coffee Bar is a high-growth operator of guest-centric, drive-thru coffee bars, offering premium caffeinated beverages and an elevated in-store experience [3] - Founded in 2008 in Beaverton, Oregon, Black Rock Coffee Bar has grown from a single 160 square foot coffee bar to one of the fastest-growing beverage companies in the U.S. by revenue [3] - The company is the largest fully company-owned coffee retailer in the country, with over 170 locations across seven states, from the Pacific Northwest to Texas [3]

Core Insights - Fate Therapeutics, Inc. is a clinical-stage biopharmaceutical company focused on developing a first-in-class pipeline of induced pluripotent stem cell (iPSC)-derived cellular immunotherapies for cancer and autoimmune diseases [1][3] Company Overview - The company utilizes a proprietary iPSC product platform to create multiplexed-engineered master iPSC lines and manufacture off-the-shelf, iPSC-derived cell products [3] - Fate Therapeutics has established a leadership position in the clinical development of iPSC-derived natural killer (NK) cell and T-cell product candidates, which are designed to deliver multiple therapeutic mechanisms [3] - The company is headquartered in San Diego, California [3] Upcoming Events - Fate Therapeutics will present at the Piper Sandler 37th Annual Healthcare Conference on December 2, 2025, in New York [1] - Company management will participate in a fireside chat at 9:00 AM ET and a cell therapy panel discussion at 12:00 PM ET [1]

Core Insights - DraftKings has launched a Spanish-language experience within its Sportsbook & Casino app, reflecting the company's commitment to customer-centric services and expanding its market reach [1][2]. Group 1: Product Development - The new Spanish-language functionality aims to enhance the user experience for Spanish-speaking players, who represent a growing segment of DraftKings' customer base [2]. - This feature will be rolled out initially to select existing customers in the U.S. and Ontario, with plans for broader availability in the coming weeks [2][3]. - The Spanish-language experience will encompass the entire customer journey, including account onboarding, navigation, betting content, gameplay, promotions, customer support, and responsible gaming resources [3]. Group 2: Company Overview - DraftKings Inc. is a digital sports entertainment and gaming company founded in 2012, headquartered in Boston, offering products in daily fantasy, regulated gaming, and digital media [4]. - The company operates sports betting in 28 states, Washington, D.C., Ontario, Canada, and Puerto Rico, and provides iGaming services in five states and Ontario [4]. - DraftKings is an official partner of major sports leagues, including the NFL, NHL, PGA TOUR, WNBA, UFC, NBA, and MLB, and also owns the leading digital lottery courier app, Jackpocket [4].

Core Insights - The merger between Galaxy Gaming, Inc. and Evolution Malta Holding Limited is progressing, with Mississippi's regulatory approval secured, leaving only two jurisdictions pending approval [1][3] - The merger agreement has been extended to July 17, 2026, demonstrating both companies' commitment to completing the transaction and enhancing innovation in the gaming industry [2][4] Regulatory Approval Process - The companies expect to receive the necessary regulatory approvals in the first quarter of 2026, with Mississippi's approval already obtained in November 2025 [3] - Both companies are actively collaborating with regulators to fulfill the remaining gaming approvals by the extended deadline [3][4] Company Statements - Evolution's CEO expressed confidence in the merger's progress and emphasized the importance of Galaxy Gaming's innovative products in strengthening Evolution's market position [4] - Galaxy Gaming's CEO highlighted the merger as a significant opportunity for both companies to enhance customer experiences across various gaming channels [4] Post-Merger Strategy - After the merger, Galaxy Gaming will operate as an independent business unit within Evolution, maintaining its unique culture while benefiting from Evolution's global resources [4] - The focus will be on driving omni-channel innovation and creating additional value for partners and players worldwide [4]

Core Insights - Daxor Corporation is expanding its Blood Volume Analysis (BVA) platform into three new facilities, indicating accelerating market adoption and its role in precision fluid management [1][2] - The company's dual-solution strategy, which includes the on-site BVA analyzer and the CLIA-certified ezBVA Lab Service, is driving strong sales momentum as clinicians increasingly adopt this diagnostic tool [2][3] Company Overview - Daxor Corporation addresses the healthcare challenge of accurately measuring blood volume, which can lead to suboptimal care and increased costs for conditions like heart failure [3] - With 50 years of experience, Daxor manufactures and distributes its FDA-cleared BVA diagnostic, providing real-time, precise data to empower clinicians in making individualized treatment decisions [3] Recent Developments - The ezBVA Lab has been adopted by various healthcare facilities, including the Upper Midwest Integrated Health System for cardiology diagnostics and an Ohio Academic Medical Center for heart failure management [6] - The Southwest Cardiology Group Practice has onboarded the new BVA Analyzer for immediate in-office volume assessment, showcasing the tool's versatility across different healthcare settings [6]

Core Viewpoint - Ollie's Bargain Outlet Holdings, Inc. will report its financial results for the third quarter of fiscal 2025 on December 9, 2025, before market opening [1] Group 1: Financial Reporting - The financial results will be discussed in a conference call hosted by the President and CEO, Eric van der Valk, and the Executive Vice President and CFO, Robert Helm, at 8:30 a.m. Eastern Time on the same day [1] - Interested parties can access the live conference call by pre-registering and will receive dial-in instructions [2] Group 2: Company Overview - Ollie's is a leading off-price retailer specializing in brand name household products, operating under the mission of selling Good Stuff Cheap® since its founding in 1982 [3] - The company utilizes a flexible buying model focusing on closeout merchandise and excess inventory, offering prices up to 70% below traditional retailers [3] - As of August 2, 2025, Ollie's operates 613 stores across 34 states, with plans for further growth [3]

Company Overview - CytomX Therapeutics, Inc. is a clinical-stage biopharmaceutical company focused on oncology, developing novel conditionally activated, masked biologics aimed at localizing treatment to the tumor microenvironment [3] - The company utilizes its PROBODY therapeutic platform to create safer and more effective cancer therapies, with a pipeline that includes antibody-drug conjugates (ADCs), T-cell engagers, and immune modulators [3] Clinical Pipeline - Current clinical-stage candidates include CX-2051, a masked ADC targeting epithelial cell adhesion molecule (EpCAM) with a topoisomerase-1 inhibitor payload, and CX-801, a masked interferon alpha-2b PROBODY cytokine [3] - CX-2051 has potential applications in various EpCAM-expressing epithelial cancers, including colorectal cancer (CRC), and was developed in collaboration with ImmunoGen [3] - CX-801 is designed for broad applicability in both immuno-oncology sensitive and insensitive tumors [3] Strategic Collaborations - CytomX has established partnerships with leading companies in oncology, including Amgen, Astellas, Bristol Myers Squibb, Regeneron, and Moderna [3] Upcoming Events - Management will participate in the 8th Annual Evercore Healthcare Conference on December 2, 2025, and the Piper Sandler 37th Annual Healthcare Conference on December 4, 2025 [2] - A live webcast of the presentations will be available on CytomX's website, and management will hold one-on-one meetings with registered investors [2]